Evidence map›Paper›PMID 33977239›Full record

ArticleIJU case reports2021

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy.

Shotaro Yasuoka, Takeshi Yuasa, Motohiro Fujiwara, Junko Fujisaki, Kentaro Inamura, Yoshinobu Komai, Noboru Numao, Shinya Yamamoto, Junji Yonese

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shotaro YasuokaDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0001-5749-0993
Takeshi YuasaDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-8924-6730
Motohiro FujiwaraDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Junko FujisakiDepartment of Gastroenterological Medicine Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Kentaro InamuraDepartment of Pathology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Yoshinobu KomaiDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Noboru NumaoDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Shinya YamamotoDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0003-0416-4697
Junji YoneseDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Japanese Foundation For Cancer Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetastatic renal cell carcinoma is treated with various regimens. As their outcomes are improving and follow-up periods are growing longer, the rate of unusual visceral metastases may increase. CASE PRESENTATION: A 68-year-old man diagnosed with lung, pancreatic, and renal metastases 9 years after left partial nephrectomy and a diagnosis of pT1a clear cell renal cell carcinoma started molecular targeted therapy using sunitinib. Nine years after the initiation of targeted therapy, a mass lesion in the esophagus was revealed by follow-up computed tomography, and endoscopic mucosal resection of the esophageal metastatic lesion was performed. One year later, a bladder tumor was detected by follow-up computed tomography. The patient underwent transurethral resection of the bladder tumor. Histological evaluation of both resected specimens disclosed clear cell renal cell carcinoma.

conclusionWe present a valuable case of metachronous esophagus and bladder metastases from renal cell carcinoma in a long-term follow-up.

Indexed as

bladder metastasisesophageal metastasisrenal cell cancer

Identifiers

PMID33977239
PMCPMC8088885
OpenAlexW3133527727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.